GSK_Annual_Report_2021

Financial Statements GlaxoSmithKline Pharmaceuticals Limited 160 ` in Lakhs As at March 31, 2021 As at March 31, 2020 a) Shares held by holding company Equity Shares of ` 10 each 960,000 (Previous year : 960,000) held by GlaxoSmithKline Pharmaceuticals Limited, the Holding Company 96.00 96.00 b) Reconciliation of the number of shares Number of Shares ` In Lakhs Number of Shares ` In Lakhs Balance at the beginning of the year 9,60,000 96.00 9,60,000 96.00 Issued during the year - - - - Balance at the end of the year 9,60,000 96.00 9,60,000 96.00 c) Rights, preferences and restrictions attached to equity shares: The company has only one class of equity shares having a par value of ` 10/- per share. Each share holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting except in case of interim dividend. In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders. d) Details of shareholders holding more than 5% shares in the company: Number of Shares Number of Shares GlaxoSmithKline Pharmaceuticals Limited, the Holding Company 9,60,000 9,60,000 {100%} {100%} ` in Lakhs For the year ended March 31, 2021 For the year ended March 31, 2020 18 REvEnUE from opErations Sale of products (gross) Sale of products 12,56.22 - Total Revenue from operations 12,56.22 - 19 OtHEr incomE Interest income 38.71 98.35 Provisions written back (net) - 47.32 Miscellaneous Income 0.78 0.01 39.49 1,45.68 20 Cost of matEriaLs consUmEd Cost of materials consumed 19,38.60 - ` in Lakhs For the year ended March 31, 2021 For the year ended March 31, 2020 21 CHangEs In InvEntoriEs Of FinisHEd Goods, Work-In- ProgrEss and tradEd goods Opening stock Work-in-progress - - Finished goods - - Traded goods - - Less: Closing stock Work-in-progress 23.98 - Finished goods 11,65.82 - Traded goods - - (11,89.80) - 22 OtHEr ExpEnsEs Manufacturing charges 3,94.87 - Rent - 0.34 Rates and taxes 4.51 5.62 Remuneration to auditors : Statutory audit fees 3.45 3.45 Tax audit fees 0.70 - Reimbursement of expenses 0.30 0.56 Reimbursement of expenses to GlaxoSmithKline Pharmaceuticals Limited 25.33 29.95 Repairs and Maintenance 2.63 0.90 Tax and consulting fees 5.53 14.35 Security guard services 24.43 23.55 Third party warehousing 5.58 4.36 Miscellaneous expenses 3.36 0.08 Provision for bad and doubtful loans and advances - 42.92 4,70.69 1,26.08 23 EARNINGS PER SHARE Earnings per share Earnings per share is calculated by dividing the profit attributable to the equity shareholders by the weighted average number of equity shares outstanding during the year. The numbers used in calculating basic and diluted earnings per equity share are as stated below: Profit /(loss) after taxation ( ` Lakhs) 57.98 (16,90.58) Weighted average number of shares (Nos) 960,000 960,000 Earnings per share (Basic and Diluted) - ` 6.04 (1,76.10) Face value per share - ` 10.00 10.00